GleamWall
中文EN

CALC CalciMedica, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1534133 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY34.5%
TTM EPS YoY152.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-763.3%
ROA-103.5%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets70.4%
Debt / equity0.00x
Current ratio4.96x
Interest coverage-14.15x

Cash quality & payout

Operating cash flow / net income1.20x
Accruals ratio21.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$15.23M$14.48M
SG&A expense$7.89M$9.73M
Operating income-$23.12M-$24.20M
Interest expense$1.42M$0
Pretax income-$29.56M-$13.70M
Income tax$0$0
Net income-$29.56M-$13.70M
EBITDA-$23.07M-$24.15M
EPS (basic)-1.97-1.22
EPS (diluted)-1.97-1.22
Weighted avg. shares (diluted)15.01M11.25M
Banking
Noninterest income$713,000$1.01M
Balance sheet
Cash & equivalents$11.52M$7.93M
Short-term investments$1.50M$10.73M
Current assets$13.53M$19.66M
PP&E, net$50,000$119,000
Total assets$13.59M$19.79M
Current liabilities$3.78M$3.68M
Total liabilities$20.23M$5.38M
Shareholders' equity-$6.64M$14.41M
Shares outstanding3.09M13.48M
Cash flow statement
Operating cash flow-$21.18M-$21.15M
Capital expenditure$28,000$8,000
Free cash flow-$21.21M-$21.15M
Investing cash flow$9.55M-$4.42M
Financing cash flow$15.21M$27.97M
Depreciation & amortization$46,000$58,000
Stock-based compensation$2.97M$2.31M

Free plan shows the latest 2 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.